AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01957059 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dosing Extension
Description: All doses of PRO053 will be administered as IV infusions. The proposed doses will be decided upon completion of the Regimen Selection Phase of Groups 2 and 3 and the Treatment Phase Group 4.
Study NCT02256943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Amitriptyline
Description: 100 mg single dose
Study NCT02256943 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tolterodine
Description: Placebo 1 mg single dose
Study NCT03346902 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: EB-001
Description: Injection of EB-001 into area of scarring (forehead)
Study NCT03346902 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 0.9% Sodium Chloride Injection
Description: Injection of Saline into area of scarring (forehead)
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: Participants will take 100 mg/day for patients with glomerular filtration rate (GFR) > 50 and 50 mg/day for GFR 30 - 49, beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
Study NCT03153293 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rAAV2-ND4
Description: a Single IVT Injection
Study NCT03701178 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: BioHPP PEEK
Description: milled BioHPP PEEK in a new material can be used as a dental restoration
Study NCT03701178 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: BioHPP PEEK
Description: milled BioHPP PEEK in a new material can be used as a dental restoration
Study NCT01855568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Single-dose Methotrexate
Description: Participants in the single-dose protocol group received intramuscular methotrexate at single dose of 50 mg/m2 on day 0 (the initial day of treatment). The β-hCG levels were then measured on day 4 and 7. If there was at least 15% β-hCG drop between day 4 and 7, the treatment was deemed successful and the participants were then followed with weekly β-hCG measurements until the results was negative. If a 15% drop on day 4 and 7 did not occur, a second dose was administrated on day 7 and β-hCG levels were then measured on day 11 and 14. Participants were referred for surgical treatment if β-hCG levels fell \<15% between day 11 and 14.
Study NCT01855568 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two-dose methotrexate protocol
Description: Participants in the two-dose protocol group received intramuscular methotrexate twice at dose of 50 mg/m2 on day 0 and 4. A third dose of methotrexate was given on day 7 if β-hCG levels did not fall 15% between day 4 and 7 after two-dosing. A fourth dose was administered on day 11 if β-hCG levels fell \<15% between day 7 and 11. Then, a final β-hCG level was checked on day 14. If a 15% drop was not seen, the medical treatment was deemed refractory and the patients were referred for surgical treatment.
Study NCT02245893 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open reduction internal fixation (ORIF)
Description: The study design is a prospective, randomized pilot clinical trial of the treatment of unstable syndesmosis injuries sustained with Weber C type fractures. Comparison will be made between two syndesmosis stabilization methods: 1) Percutaneous (closed) reduction using syndesmosis fixation by SCREW 2) Open reduction (ORIF) with ART repair of the anterior ligament and stabilization of the syndesmosis by use of a syndesmosis screw.
Study NCT02181621 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Iodosorb
Description: Cadexomer iodine gel
Study NCT02181621 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Solosite gel
Description: Hydrogel
Study NCT02697929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sugammadex
Study NCT02697929 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Neostigmine
Study NCT04143438 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: EOS 3D imaging protocol pre- and post-surgery
Description: Patients will undergo a EOS 3D Imaging protocol before and 6 months after undergoing patello-femoral surgery. This protocol is already used routinely in the hospital before every patello-femoral surgery.
Study NCT02319083 — intervention group
Intervention type: PROCEDURE
Intervention: Coronary artery bypass surgery
Description: Patients will undergo coronary artery bypass grafting
Study NCT04534725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Interferon alfa
Description: intranasal spray
Study NCT04534725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: oral tablet
Study NCT04534725 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenzilumab
Description: intravenous infusion
Study NCT04096885 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Blood and urine samples, skin and stool swabs
Description: Blood samples will be collected before surgery, on the first postoperative day and after 3-8 weeks. Urine samples will be collected after surgery and after 3-8 weeks. Stool and skin swabs will be collected before surgery.
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nitazoxanide
Description: Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Nitazoxanide
Description: Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
Study NCT06143605 — intervention group
Intervention type: PROCEDURE
Intervention: salvage treatment
Description: salvage radical surgery or endoscopic resection
Study NCT04378985 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Wearing a Wearable device (Fitbit inspire HR)
Description: 'Wearing a wearable device (the smart watch) for 8 weeks~The smart watch to be used in this study is Fitbit Inspire HR. This is a device that has a high worldwide use rate and has active research on its accuracy. It is worn like a normal watch, and it can check heart rate, exercise level, energy consumed, and sleep quality. The values can be checked in real-time on a smartphone application.'
Study NCT04052724 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intervention group LINGI
Description: Intervention based on cognitive behavioural therapy principles and culturally adapted to Lithuanian population. Intervention's main purpose is to reduce caregiver burden and increase quality of life. Intervention contains psycho-educational elements as well as examples and exercises.
Study NCT01198379 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aspirin
Description: aspirin 100 mg qd for 3 years
Study NCT01198379 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01522885 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: KatGuide versus conventional method (forceps)
Description: According to randomization Chest tubes are placed in the pleural cavity by using the KatGuide device.
Study NCT01522885 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Chest tube insertion
Description: The chest tube is placed in the pleural cavity by using a forceps (conventional method) or KatGuide
Study NCT00678496 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CBT Software
Description: Beating the Blues is a CBT-based software package for patients with anxiety and/or depression. The CBT strategies used include: identifying thinking errors, challenging automatic negative thoughts, modifying attributional style and identifying core beliefs. The behavioural techniques used include graded exposure, sleep management, problem solving, task breakdown and activity scheduling. The programme consists of a 15 minute Introduction to Therapy video plus eight computer-interactive sessions of approximately 50 minutes each in duration. Each session consists of a mix of cognitive and behavioural strategies, which are customised to the patient's individual problems. The eight computer sessions are designed to be taken weekly, or thereabouts, and each session builds on the previous one.
Study NCT00678496 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Treatment as usual
Description: Participants in the usual care arm are asked to refrain from accessing psychological services during their participation in the study, but may be prescribed anti-depressants or referred to a counsellor by their general practitioner.
Study NCT02368444 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy and Yoga
Description: Group Cognitive Behavioral Therapy Treatment and Yoga Program
Study NCT02165540 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Doula
Description: A specially trained support person or doula will accompany the patient to offer physical and emotional support during the procedure.
Study NCT00757523 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epiduo Gel
Description: Epiduo Gel (combination of 0.1% adapalene and 2.5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
Study NCT00757523 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Duac Gel
Description: Duac Akne Gel (combination of 1% clindamycin phosphate and 5% benzoyl peroxide (BPO) in a gel preparation). Treatments administered once-daily in the evening for 12 weeks
Study NCT01040832 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
Study NCT01040832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: Cetuximab weekly (initial dose 400 milligram per square meter \[mg/m\^2\] over 120 minutes followed by 250 mg/m\^2 intravenous infusion over 60 minutes) will be administered in 3-week treatment cycle until disease progression. The total treatment period will be approximately 18 months.
Study NCT01040832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EMD 1201081
Description: EMD 1201081 weekly (0.32 milligram per kilogram \[mg/kg\] by subcutaneous injection) will be administered in 3-week treatment cycle until disease progression. Subjects who will discontinue cetuximab due to toxicity in cetuximab monotherapy, could continue to receive EMD 1201081 monotherapy until disease progression. The total treatment period will be approximately 18 months.
Study NCT04336150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises
Description: See information included in arm/group descriptions.
Study NCT04336150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive maneuver
Description: See information included in arm/group descriptions.
Study NCT04336150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive exercises plus pelvic floor muscle contraction
Description: See information included in arm/group descriptions.
Study NCT04336150 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hypopressive maneuver plus pelvic floor muscle contraction
Description: See information included in arm/group descriptions.
Study NCT02158221 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: PACAP
Description: Pituitary adenylate cyclase-activating polypeptide (PACAP)
Study NCT00873444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ Acetabular System
Description: A cementless acetabular cup with ceramic liner for use in total hip replacement
Study NCT00873444 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Pinnacle™ Acetabular System
Description: A cementless acetabular cup with metal liner for use in total hip replacement
Study NCT05506371 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Az+SRP
Description: Azithromycin as an adjunct to scaling and root planning in the treatment of periodontitis
Study NCT05506371 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: SRP
Description: Scaling and root planning (SRP) treatment of periodontitis
Study NCT05506371 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: No interventions
Description: Diagnostocs to confirm the healthy state of the gingiva
Study NCT05314348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: High-density surface EMG
Description: High-density surface EMG for fasciculation detection
Study NCT05314348 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ultrasound
Description: Ultrasound for fasciculation detection
Study NCT04111822 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: red blood cells transfusion, tranexamic acid (TXA) and fibrinogen concentrate
Description: Phase III, randomized, multicenter, open-label and parallel group pilot study, which aims to study mortality at 28 days of admission in patients with septic shock treated with usual management and patients treated with ascorbic acid, thiamine and hydrocortisone added to usual driving
Study NCT04111822 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: on crystalloid fluid and Tranexamic acid
Description: Resuscitation with crystalloids, Performing culture battery, antibiotic therapy
Study NCT03988712 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Colonoscopy, gastroscopy, virtual colonoscopy, CT scan
Description: Patients referred with a suspected bowel malignancy were subjected to top and bottom endoscopic examination or a cross sectional imaging like CT scan and MRI scan.
Study NCT00215501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine
Description: Orally twice a day for 14 days (dosage will vary)
Study NCT00215501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil (5-FU)
Description: Continuous infusion 24 hours a day for 14 days (Days 1-14) Dosage will vary
Study NCT00413478 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Azacytidine
Description: Starting dose level: 75mg/m\^2 subcutaneously daily for seven days. Treatment cycles will be repeated every 3-8 weeks.
Study NCT02220127 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GKR with a single shot of the 8 mm collimator
Description: Gamma Knife Radiosurgery (GKR) with a single shot of the 8 mm collimator at an isodose above 90%.
Study NCT02220127 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: GKR with a single shot of the 4 mm collimator
Description: Gamma Knife Radiosurgery (GKR) with a single shot of the 4 mm collimator at an isodose between the 40% and 90%.
Study NCT00215501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Intravenously weekly for 2 weeks (given after cisplatin) followed by a one-week rest period
Study NCT00215501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: Intravenously weekly for 2 weeks followed by a one week rest period
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ribavirin
Description: Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Ribavirin
Description: Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
Study NCT02696226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAVR Warfarin
Description: Warfarin treatment for 12 weeks with a target INR of 2-3 Warfarin treatment to begin on postoperative day 1-3 according to the patient's clinical status When warfarin treatment is discontinued, patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
Study NCT02696226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAVR Aspirin
Description: Aspirin (81 mg/day) to begin within 1-3 postoperative days according to the patient's clinical status and continue indefinitely per standard of care.
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydroxychloroquine
Description: Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
Study NCT04605588 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Hydroxychloroquine
Description: Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
Study NCT02527265 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Afrezza
Description: Pharmaceutical form: powder~Route of administration: inhalation
Study NCT02835521 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Reception
Study NCT02835521 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Joint injection with triamcinolone hexacetonide
Description: joint injection with corticosteroids
Study NCT02835521 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Joint injection with triamcinolone hexacetonide
Description: joint injection with corticosteroids
Study NCT03824054 — intervention group
Intervention type: PROCEDURE
Intervention: colorectal resection
Description: Surgery includes laparoscopic resection of all visible endometriosis, including resection of the affected bowel with primary anastomosis
Study NCT02913859 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiotherapy to the pelvis
Description: Radiotherapy to the pelvis and prostate
Study NCT02913859 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hormonal therapy (LHRH agonist and/or antiandrogens)
Description: life-long hormonal therapy (LHRH agonist and/or antiandrogens)
Study NCT02913859 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hormonal therapy (LHRH agonist and/or antiandrogens)
Description: life-long hormonal therapy (LHRH agonist and/or antiandrogens)
Study NCT04667728 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Professional continuous glucose monitoring (CGM) sensor (iPro™2)
Description: Professional continuous glucose monitoring (CGM) sensor (iPro™2) following treatment adjustments and personalized diet plan
Study NCT01506336 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: masitinib
Description: masitinib 12 mg/kg/day
Study NCT01506336 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: sunitinib
Description: sunitinib 50 mg/day
Study NCT02696226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVR Warfarin and clopidogrel
Description: Begin Warfarin and clopidogrel (75 mg/day) treatment within 1-3 days postop for 12 weeks with a target INR of 2-3 When warfarin is discontinued, begin aspirin (81 mg/day) and continue aspirin/clopidogrel for 12 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
Study NCT02696226 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TAVR Aspirin and clopidogrel
Description: Aspirin (81 mg/day) and clopidogrel (75 mg/day) in periprocedural period and continue for 24 weeks At 24 weeks, study treatment will end and patients will be treated according to standard of care (aspirin 81 mg/day) indefinitely
Study NCT04845438 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
Description: fibrogastroscopy, biopsy of the gastric mucosa, microscopy biopsy materials, using Bile Reflux Index
Study NCT01046747 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Placement of external fixation pins
Description: The fractures will be treated according to standard of care. If the external fixation is to be used as a staging procedure, then this will be removed and an internal fixation procedure will be performed. The pin sites will be checked daily according to standard of care. All individuals involved in the examination of the pin sites will receive a standardized training in the grading of pin tract infection and loosening. Each pin site will be graded individually by three persons to evaluate internal accuracy of our grading. Pin tract infections will be first graded as yes or no, and then graded according to the Modified Joglekar Classification (Grade 0-4, Grade 0: no erythema, no drainage; Grade 1: erythema, no drainage OR no erythema with serous drainage; Grade 2: erythema, serous drainage; Grade 3: erythema, purulent drainage; Grade 4: gross pin loosening). Pin loosening will be evaluated at the time of pin removal and graded as either yes or no.
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will take one pill daily beginning on the day prior to surgery and continuing through hospitalization, up to 10 days.
Study NCT02741687 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Supplemental insulin (insulin lispro)
Description: Supplemental insulin lispro will be administered before meals, in addition to scheduled insulin dose, following the supplemental insulin scale protocol. At bedtime, half of supplemental sliding scale insulin starting at blood glucose (BG) >240 mg/dL will be given. If a patient is unable to eat, supplemental insulin will be administered every 6 hours with the lowest number of units for that appropriate BG level.~For subjects receiving supplemental insulin lispro with BG levels greater than 180 mg/dL, the supplemental insulin scale is as follows:~* BG between 181-220 mg/dL; 2-4 units of insulin lispro~* BG between 221-260 mg/dL; 3-5 units of insulin lispro~* BG between 261-300 mg/dL; 4-6 units of insulin lispro~* BG between 301-350 mg/dL; 5-7 units of insulin lispro~* BG between 351-400 mg/dL; 6-8 units of insulin lispro~* BG > 400 mg/dL; 7-9 units of insulin lispro